Composite tissue allotransplantation immunology

Archives of Plastic Surgery

Volumn 40, Issue 2, 2013, Pages 141-153

  Eun, Seok Chan ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AZATHIOPRINE; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CALCINEURIN; CALCIUM; CD3 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYCLOSPORIN; DACLIZUMAB; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LYMPHOTOXIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ALLOTRANSPLANTATION; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; CHRONIC GRAFT REJECTION; CLINICAL TRIAL (TOPIC); COMPOSITE TISSUE ALLOTRANSPLANTATION; DONOR; GRAFT REJECTION; HISTOLOGY; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MAINTENANCE THERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REGULATORY T LYMPHOCYTE; RISK; T CELL DEPLETION; T LYMPHOCYTE;

EID: 84875354357     PISSN: 22346163     EISSN: 22346171     Source Type: Journal    
DOI: 10.5999/aps.2013.40.2.141     Document Type: Article

References (87)

1. Tai C, Goldenberg M, Schuster KM, et al. Composite tissue allotransplantation. J Invest Surg 2003;16:193-201.
2. Cendales LC, Xu H, Bacher J, et al. Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation 2005;80:1447-54.
3. Dubernard JM, Owen E, Herzberg G, et al. Human hand allograft: report on first 6 months. Lancet 1999;353:1315-20.
4. Petit F, Minns AB, Dubernard JM, et al. Composite tissue allotransplantation and reconstructive surgery: first clinical applications. Ann Surg 2003;237:19-25.
5. Devauchelle B, Badet L, Lengele B, et al. First human face allograft: early report. Lancet 2006;368:203-9.
6. Lanzetta M, Petruzzo P, Margreiter R, et al. The International Registry on Hand and Composite Tissue Transplantation. Transplantation 2005;79:1210-4.
7. Lechler RI, Sykes M, Thomson AW, et al. Organ transplantation--how much of the promise has been realized? Nat Med 2005;11:605-13.
8. Calne RY. Prope tolerance: the future of organ transplantation from the laboratory to the clinic. Int Immunopharmacol 2005;5:163-7.
9. Siemionow M, Klimczak A. Basics of immune responses in transplantation in preparation for application of composite tissue allografts in plastic and reconstructive surgery: part I. Plast Reconstr Surg 2008;121:4e-12e.
10. Womer KL, Stone JR, Murphy B, et al. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol 2001;12:2500-6.
11. Womer KL, Sayegh MH, Auchincloss H Jr. Involvement of the direct and indirect pathways of allorecognition in tolerance induction. Philos Trans R Soc Lond B Biol Sci 2001; 356:639-47.
12. Ensminger SM, Spriewald BM, Witzke O, et al. Indirect allorecognition can play an important role in the development of transplant arteriosclerosis. Transplantation 2002;73:279-86.
13. Lee RS, Yamada K, Houser SL, et al. Indirect allorecognition promotes the development of cardiac allograft vasculopathy. Transplant Proc 2001;33:308-10.
14. Rogers NJ, Lechler RI. Allorecognition. Am J Transplant 2001;1:97-102.
15. Cendales LC, Kirk AD, Moresi JM, et al. Composite tissue allotransplantation: classification of clinical acute skin rejection. Transplantation 2005;80:1676-80.
16. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004;4:1562-6.
17. Lee WP, Yaremchuk MJ, Pan YC, et al. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg 1991;87:401-11.
18. Buttemeyer R, Jones NF, Min Z, et al. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. Plast Reconstr Surg 1996; 97:139-48.
19. Rocha PN, Plumb TJ, Crowley SD, et al. Effector mechanisms in transplant rejection. Immunol Rev 2003;196:51-64.
20. Aw MM. Transplant immunology. J Pediatr Surg 2003;38: 1275-80.
21. Hancock WW, Gao W, Shemmeri N, et al. Immunopathogenesis of accelerated allograft rejection in sensitized recipients: humoral and nonhumoral mechanisms. Transplantation 2002;73:1392-7.
22. Monaco AP. Prospects and strategies for clinical tolerance. Transplant Proc 2004;36:227-31.
23. Kanitakis J, Jullien D, Petruzzo P, et al. Clinicopathologic features of graft rejection of the first human hand allograft. Transplantation 2003;76:688-93.
24. Petruzzo P, Badet L, Gazarian A, et al. Bilateral hand transplantation: six years after the first case. Am J Transplant 2006;6:1718-24.
25. Williams JM, Holzknecht ZE, Plummer TB, et al. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation 2004;78:1471-8.
26. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005;5:2611-8.
27. Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 2000;20:126-47.
28. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995;59:313-8.
29. Joosten SA, Sijpkens YW, van Kooten C, et al. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005;68:1-13.
30. Womer KL, Lee RS, Madsen JC, et al. Tolerance and chronic rejection. Philos Trans R Soc Lond B Biol Sci 2001;356: 727-38.
31. Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 1998;65:1533-42.
32. Singer P, Shapiro H, Cohen J. Brain death and organ damage: the modulating effects of nutrition. Transplantation 2005;80:1363-8.
33. Kuecuek O, Mantouvalou L, Klemz R, et al. Significant reduction of proinflammatory cytokines by treatment of the brain-dead donor. Transplant Proc 2005;37:387-8.
34. Takada M, Nadeau KC, Shaw GD, et al. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney: inhibition by a soluble P-selectin ligand. J Clin Invest 1997;99:2682-90.
35. Ozer K, Oke R, Gurunluoglu R, et al. Induction of tolerance to hind limb allografts in rats receiving cyclosporine A and antilymphocyte serum: effect of duration of the treatment. Transplantation 2003;75:31-6.
36. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52- specific monoclonal antibody alemtuzumab (CAMPATH- 1H). Transplantation 2003;76:120-9.
37. Siemionow M, Klimczak A. Tolerance and future directions for composite tissue allograft transplants: part II. Plast Reconstr Surg 2009;123:7e-17e.
38. Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc 1998;30:1573-9.
39. Gorantla VS, Barker JH, Jones JW Jr, et al. Immunosuppressive agents in transplantation: mechanisms of action and current anti-rejection strategies. Microsurgery 2000;20:420-9.
40. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
41. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59:3-16.
42. Goggins WC, Fisher RA, Dattilo JB, et al. Analysis of funcional renal allograft tolerance with single-dose rapamycin based induction immunosuppression. Transplantation 1997; 63:310-4.
43. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80:S254-64.
44. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005;200:505-15.
45. Engl T, Makarevic J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005;5:4.
46. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003;76:1289-93.
47. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361:1502-10.
48. Jones NF. Concerns about human hand transplantation in the 21st century. J Hand Surg Am 2002;27:771-87.
49. Thaunat O, Badet L, El-Jaafari A, et al. Composite tissue allograft extends a helping hand to transplant immunologists. Am J Transplant 2006;6:2238-42.
50. Petruzzo P, Revillard JP, Kanitakis J, et al. First human double hand transplantation: efficacy of a conventional immunosuppressive protocol. Clin Transplant 2003;17:455-60.
51. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;338:1813-21.
52. Noel PJ, Boise LH, Green JM, et al. CD28 costimulation prevents cell death during primary T cell activation. J Immunol 1996;157:636-42.
53. Zheng XX, Sanchez-Fueyo A, Domenig C, et al. The balance of deletion and regulation in allograft tolerance. Immunol Rev 2003;196:75-84.
54. Papiernik M, de Moraes ML, Pontoux C, et al. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1998; 10:371-8.
55. Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006;6:876-83.
56. Wood K, Sachs DH. Chimerism and transplantation tolerance: cause and effect. Immunol Today 1996;17:584-7.
57. Sachs DH. Mixed chimerism as an approach to transplantation tolerance. Clin Immunol 2000;95:S63-8.
58. Monaco AP. Antilymphocyte serum, donor bone marrow and tolerance to allografts: the journey is the reward. Transplant Proc 1999;31:67-71.
59. Wekerle T, Sykes M. Mixed chimerism and transplantation tolerance. Annu Rev Med 2001;52:353-70.
60. Starzl TE, Demetris AJ, Trucco M, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993;17:1127-52.
61. Starzl TE, Demetris AJ, Murase N, et al. The lost chord: microchimerism and allograft survival. Immunol Today 1996; 17:577-84.
62. Starzl TE, Demetris AJ. Transplantation tolerance, microchimerism, and the two-way paradigm. Theor Med Bioeth 1998;19:441-55.
63. Kanitakis J, Jullien D, Claudy A, et al. Microchimerism in a human hand allograft. Lancet 1999;354:1820-1.
64. Yu X, Carpenter P, Anasetti C. Advances in transplantation tolerance. Lancet 2001;357:1959-63.
65. Siemionow M, Ortak T, Izycki D, et al. Induction of tolerance in composite-tissue allografts. Transplantation 2002; 74:1211-7.
66. Jonuleit H, Schmitt E, Kakirman H, et al. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 2002;196:255-60.
67. Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol 2006;6:520-31.
68. Sprent J, Kishimoto H. The thymus and negative selection. Immunol Rev 2002;185:126-35.
69. Kyewski B, Derbinski J. Self-representation in the thymus: an extended view. Nat Rev Immunol 2004;4:688-98.
70. Anderson G, Partington KM, Jenkinson EJ. Differential effects of peptide diversity and stromal cell type in positive and negative selection in the thymus. J Immunol 1998; 161:6599-603.
71. Li L, Boussiotis VA. Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. J Mol Med (Berl) 2006;84:887-99.
72. Siemionow M, Izycki D, Ozer K, et al. Role of thymus in operational tolerance induction in limb allograft transplant model. Transplantation 2006;81:1568-76.
73. Belz GT, Behrens GM, Smith CM, et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002;196: 1099-104.
74. Coulson MT, Jablonski P, Howden BO, et al. Beyond operational tolerance: effect of ischemic injury on development of chronic damage in renal grafts. Transplantation 2005;80: 353-61.
75. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998;351:1701-2.
76. Zhong R, Tucker J, Grant D, et al. Long-term survival and functional tolerance of baboon to monkey kidney and liver transplantation: a preliminary report. Transplant Proc 1996; 28:762.
77. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007;7:309-19.
78. Grohmann U, Bianchi R, Orabona C, et al. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J Immunol 2003;171:2581-7.
79. Belz GT, Heath WR, Carbone FR. The role of dendritic cell subsets in selection between tolerance and immunity. Immunol Cell Biol 2002;80:463-8.
80. Adorini L, Giarratana N, Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004;16:127-34.
81. Taner T, Hackstein H, Wang Z, et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005;5:228-36.
82. Ciancio G, Miller J, Garcia-Morales RO, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation 2001;71:827-35.
83. Kreisel D, Petrowsky H, Krasinskas AM, et al. The role of passenger leukocyte genotype in rejection and acceptance of rat liver allografts. Transplantation 2002;73:1501-7.
84. Ko S, Deiwick A, Jager MD, et al. The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat. Nat Med 1999;5:1292-7.
85. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-8.
86. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
87. Jonuleit H, Adema G, Schmitt E. Immune regulation by regulatory T cells: implications for transplantation. Transpl Immunol 2003;11:267-76.